{"classes":[{"categories":[{"measurements":[{"comment":"Not reached at this time.","groupId":"OG000","lowerLimit":"6.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Overall survival is measured as the interval from first study treatment until date of death, or date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of either 2.3, 3, or 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.","id":"OG000","title":"MLN9708 Combined Dose Escalation"}],"paramType":"MEDIAN","populationDescription":"All patients with measurable or evaluable disease at baseline who receive at least 1 dose of MLN9708 and undergo at least one post-baseline disease assessment. Pre-specified in Protocol to calculate PFS for all participants and for all patients receiving the MTD. Because the MTD was not reached, this analysis was only performed on all participants.","reportingStatus":"POSTED","timeFrame":"every 8 weeks for approximately 24 weeks after ASCT, then every 3 months thereafter for 2 years.","title":"Median Overall Survival (OS) at 2 Years Post-allogeneic Stem Cell Transplant (ASCT)","type":"SECONDARY","unitOfMeasure":"months"}